• Oligonucleotide Separations with RP Phases

    HPLC, UHPLC

    Oligonucleotide Separations with RP Phases

    Therapeutic oligos represent an important area of research in the pharmaceutical industry today. These drug candidates are typically 8-50 nucleotides long and contain single-stranded DNA or RNA. Oligonucleotides are typically analysed using ion-pairing chromatography. Oligonucleotides are easily degraded via phosphodiester-cleaving enzymes. However, with a thiophosphate modified phosphate group, the stability significantly increases. Phosphorothioate modified oligos will have a stereocenter at each modified phosphate group, leading to 2n-1 diastereomers, all with an individual retention time in the chromatography. For a 20-nucleotide long oligo, that’s 524 288 species present. The partial resolution of these species results in peak broadening, further complicating chromatographic separation. To resolve the problem, ion-pairing agents with longer alkyl chains can be used.

    In a study of the influence of stationary phase and ion-pairing agent on the separation of oligos, Kromasil Phenyl showed to be a very good choice when separating oligonucleotides in general, exhibiting very sharp peaks, and good selectivity.

    View these applications on www.kromasil.com/oligos.


    Events

    SETAC Europe

    May 11 2025 Vienna, Austria

    MSB 2025

    May 18 2025 Tempe. AZ, USA

    ChemUK 2025

    May 21 2025 Birmingham, UK

    ASMS Conference

    Jun 01 2025 Baltimore, MD, USA

    HPLC 2025

    Jun 15 2025 Bruges, Belgium

    View all events

    Great Job...
    The latest issue will be with you shortly
    Sign up to Chromatography Today for FREE.
    Register and get the eBulletin, a Monthly email packed with the latest Chromatography products, news and services. Join us and get the latest information first.